투석환자의 이차성 부갑상선 기능 항진증 치료에서 cinacalcet의 유효성과 안전성 및 사용 적정성 평가
Efficacy and Safety of Cinacalcet for Secondary Hyperparathyroidism in Dialysis Patients and Drug Use Evaluation
2
조회
0
다운로드
1
인용
0
참고문헌
키워드
초록
Background: Secondary hyperparathyroidism (SHPT) is common in patients with chronic kidney disease, affecting most of those who are receiving dialysis. Cinacalcet, a novel calcimimetic, targets the calcium-sensing receptor to lower PTH levels in dialysis patients. Objective: This study aimed to assess efficacy, safety and appropriateness of use of cinacalcet in dialysis patients. Method: This retrospective study was performed on total 24 cases with identified intact parathyroid hormone (iPTH), serum calcium and phosphorus levels before and 4 weeks after cinacalcet initiation at a teaching hospital from July 1st, 2011 to October 31st, 2012. Results: Cinacalcet decreased iPTH by 19% from baseline after 4weeks treatment and it was statistically significant (p<0.001). Cinacalcet also significantly decreased iPTH levels regardless of dialysis modality (hemodialysis group versus peritoneal dialysis group) and severity of SHPT (iPTH 300-800 pg/ml group versus iPTH >800 pg/ml group). Serum calcium, phosphorus and Ca x P levels were decreased without statistical significance. Gastrointestinal events, headache and hypocalcemia were the most common side effects. Monitoring for iPTH and serum calcium was not performed appropriately. 43.7% patients initiated cinacalcet therapy at serum calcium level< 9.0 mg/dl. Conclusion: In conclusion, cinacalcet lowers parathyroid hormone levels with no serious side effects. However, it is required to avoid cinacalcet treatment in patients with low serum calcium levels and monitor iPTH and serum calcium levels during cinacalcet administration.
Abstract
Background: Secondary hyperparathyroidism (SHPT) is common in patients with chronic kidney disease, affecting most of those who are receiving dialysis. Cinacalcet, a novel calcimimetic, targets the calcium-sensing receptor to lower PTH levels in dialysis patients. Objective: This study aimed to assess efficacy, safety and appropriateness of use of cinacalcet in dialysis patients. Method: This retrospective study was performed on total 24 cases with identified intact parathyroid hormone (iPTH), serum calcium and phosphorus levels before and 4 weeks after cinacalcet initiation at a teaching hospital from July 1st, 2011 to October 31st, 2012. Results: Cinacalcet decreased iPTH by 19% from baseline after 4weeks treatment and it was statistically significant (p<0.001). Cinacalcet also significantly decreased iPTH levels regardless of dialysis modality (hemodialysis group versus peritoneal dialysis group) and severity of SHPT (iPTH 300-800 pg/ml group versus iPTH >800 pg/ml group). Serum calcium, phosphorus and Ca x P levels were decreased without statistical significance. Gastrointestinal events, headache and hypocalcemia were the most common side effects. Monitoring for iPTH and serum calcium was not performed appropriately. 43.7% patients initiated cinacalcet therapy at serum calcium level< 9.0 mg/dl. Conclusion: In conclusion, cinacalcet lowers parathyroid hormone levels with no serious side effects. However, it is required to avoid cinacalcet treatment in patients with low serum calcium levels and monitor iPTH and serum calcium levels during cinacalcet administration.
참고문헌 (31)
- Rodriguez M, "The calcium-sensing receptor: a key factor in the pathogenesis of secondary hyperparathyroidism", Am J Physiol Renal Physiol, 288, pp.F253~264 (2005)
- Salem MM, "Hyperparathyroidism in the hemodialysis population : A survey of 612 patients", Am J Kidney Dis, 29, pp.862~865 (1997)
- Billa V, "High prevalence of hyperparathyroidism among peritoneal dialysis patients: A review of 176 patients", Perit Dial Int, 20, pp.315~321 (2000)
- Pitts TO, "Hyperparathyroidism and 1,25-dihydroxyvitamin D deficiency in mild, moderate, and severe renal failure", J Clin Endocrinol Metab, 67, pp.876~881 (1988)
- St. John A, "Determinants of intact parathyroid hormone and free 1,25-dihydroxyvitamin D levels in mild and moderate renal failure", Nephron, 61, pp.422~427 (1992)
- Naveh-Many T, "Parathyroid cell proliferation in normal and chronic renal failure rats. The effects of calcium, phosphorus, and vitamin D", J Clin Invest, 96(4), pp.1786~1793 (1995)
- Rickers H, "Serum concentrations of vitamin D metabolites in different degrees of impaired renal function. Estimation of renal and extrarenal secretion rate of 24,25-dihydroxyvitamin D", Nephron, 39(3), pp.267~271 (1985)
- Coladonato JA, "Secondary hyperparathyroidism and its therapy as a cardiovascular risk factor among endstage renal disease patients", Adv Ren Replace Ther, 9, pp.193~199 (2002)
- Joy MS, "Outcomes of secondary hyperparathyroidism in chronic kidney disease and the direct costs of treatment", J Manag Care Pharm, 13, pp.397~411 (2007)
- Martin KJ, "Metabolic bone disease in chronic kidney disease", J Am Soc Nephrol, 18, pp.875~885 (2007)
- Kalantar-Zadeh K, "Survival predictability of time-varying indicators of bone disease in maintenance hemodialysis patients", Kidney Int, 70, pp.771~780 (2006)
- Gutierrez OM, "Fibroblast growth factor 23 and mortality among patients undergoing hemodialysis", N Engl J Med, 359, pp.584~592 (2008)
- Goodman WG, "Development of adynamic bone in patients with secondary hyperparathyroidism after intermittent calcitriol therapy", Kidney Int, 46(4), pp.1160~1166 (1994)
- National Kidney Foundation, "K", DOQI clinical practice guidelines for bone metabolism and disease in chronic kidney disease, 2003, pp.42(suppl 3), S1~S201
- Wetmore JB, "Calcimimetics or vitamin D analogs for suppressing parathyroid hormone in end-stage renal disease: time for a paradigm shift", Nat Clin Pract Nephrol, 5, pp.24~ (2009)
- Brown AJ, , Am J Physiol, 277, pp.F157-~F175 (1999)
- Slatopolsky E, "New vitamin D analogs", Kidney Int, 63(suppl 85), pp.S83~S87 (2003)
- Sprague SM, "Paricalcitol versus calcitriol in the treatment of secondary hyperparathyroidism", Kidney Int, 63(4), pp.1483~1490 (2003)
- Mittman N, "Comparison of paricalcitol and calcitriol therapy for the treatment of secondary hyperparathyroidism in patients on maintenance dialysis", American Society of Nephrology Renal Week conference (2004)
- Joy MS, "Calcimimetics and the treatment of primary and secondary hyperparathyroidism", Ann Pharmacother, 38, pp.1871~1880 (2004)
- Amgen, "Thousand Oaks" (2004), Amgen
- Akiba T, "Dose determination of cinacalcet hydrochloride in Japanese hemodialysis patients with secondary hyperparathyroidism", Ther Apher Dial, 12, pp.117~125 (2008)
- Block GA, "Cinacalcet for secondary hyperparathyroidism in patients receiving hemodialysis", New Eng J Med, 350, pp.1516~1525 (2004)
- Raggi P, "The ADVANCE study: a randomized study to evaluate the effects of cinacalcet plus low-dose vitamin D on vascular calcification in patients on hemodialysis", Nephrol Dial Transplant, 26(4), pp.1327~1339 (2001)
- Messa P, "Calcimimetics in peritoneal dialysis patients", Contrib Nephrol, 178, pp.143~149 (2012)
- Lindberg JS, "Cinacalcet HCl, an Oral calcimimetic agent for the treatment of secondary hyperparathyroidism in hemodialysis and peritoneal dialysis: A Randomized, Double-Blind, Multicenter Study", J Am Soc Nephrol, 16, pp.800~807 (2005)
- Portolés J, "Cinacalcet in patients on peritoneal dialysis with moderate to severe hyperparathyroidism resistant to conventional treatment, a one-year, prospective study", Nefrologia, 28(4), pp.419~424 (2008)
- "Ministry of food and drug safety/ezdrug"[URL]
- 허재헌, "복약지도 만족도가 복약순응도에 미치는 영향 : 외래환자를 대상으로", 한국임상약학회지, 19(2), pp.110~119 (2009), 한국임상약학회
- 나현오, "원외처방환자에 대한 복약지도 현황 및 만족도 조사", 한국임상약학회지, 16(2), pp.92~95 (2006), 한국임상약학회
- Lee JE, "Ca and P Levels in ESRD patients and the evaluation of a patient education", J Kor Soc Health-Syst Pharm, 16(4), pp.489~494 (1999)